OGR for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General prescription drug affordability and access. Intellectual Property issues. PDUFA Reauthorization; H.R.7667, Food and Drug Amendments of 2022; S.4348, FDASLA Act of 2022; H.R.2617, Consolidated Appropriations Act, 2023. Provisions related to the pharmaceutical industry; FY2023 Appropriations Process; monitoring COVID Supplemental Funding. Privacy issues; H.R.8152, American Data Privacy and Protection Act. 340B drug discount program policy issues. Clinical trial diversity issues. Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Medicare/Medicaid MMM
Medicare Part D access and drug pricing negotiation. Compulsory licensing policy issues. Insulin policy issues; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (draft legislation); S.3700, Affordable Insulin Now Act; implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169).
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Trade (domestic/foreign) TRD
Issues related to WTO TRIPS Waiver.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.